IONIS PHARMACEUTICALS INC 8-K

What Happened

• Ionis Pharmaceuticals (IONS) filed an 8-K on March 9, 2026 announcing that directors B. Lynne Parshall and Joseph H. Wender will retire at the end of their current terms and will not seek re-election at the 2026 Annual Meeting. Ms. Parshall has served on the Board for over 25 years and previously held executive roles (COO, CFO) for 26+ years. Mr. Wender has served on the Board for over 32 years and is the Lead Independent Director.
• The Company also announced that Peter N. Reikes will rejoin the Board effective June 4, 2026. Mr. Reikes most recently served as senior strategy advisor at ARPA-H (Dec 2024–Feb 2026), was a senior advisor to the FDA for over three years, and previously served on Ionis’s Board from 2018–2021.

Key Details

• Retirement timing: Both Parshall and Wender will retire at the end of their current terms and will not stand for re-election at the 2026 Annual Meeting (June 2026).
• New director start date: Peter N. Reikes will rejoin the Board on June 4, 2026.
• Compensation and agreements: Reikes will receive the Company’s standard non-employee director cash and automatic equity grants per the Company’s Third Amended Non-Employee Director Compensation Policy and will sign the standard indemnity agreement.
• Background: Reikes’ recent roles include senior strategy advisor at ARPA-H and senior advisor to FDA; he also has investment banking experience at Stifel and prior service on Ionis’s Board (2018–2021).

Why It Matters

• Governance impact: The Board will lose two long-tenured directors with deep company and financial/governance experience (including the Lead Independent Director), which may affect board continuity and committee membership (Compliance, Finance, Compensation, Nominating/Governance).
• Replacement and expertise: Reikes’ return brings regulatory and government relations experience (FDA, ARPA-H) and industry board experience, which could be relevant to Ionis’s regulatory strategy and external partnerships.
• No management or financial changes were reported; the filing is limited to Board composition updates and the company furnished a press release as Exhibit 99.1.